Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1976 1
1977 1
1979 2
1986 4
1992 1
1993 4
1994 1
1996 1
1998 4
1999 1
2000 2
2001 5
2002 1
2003 3
2004 1
2005 3
2006 4
2007 5
2008 4
2009 8
2010 6
2011 13
2012 4
2013 5
2014 5
2015 4
2016 10
2017 12
2018 18
2019 23
2020 17
2021 17
2022 21
2023 28
2024 29
2025 27

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

263 results

Results by year

Filters applied: . Clear all
Page 1
Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
Choueiri TK, Powles T, Burotto M, Escudier B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U, Shah AY, Suárez C, Hamzaj A, Goh JC, Barrios C, Richardet M, Porta C, Kowalyszyn R, Feregrino JP, Żołnierek J, Pook D, Kessler ER, Tomita Y, Mizuno R, Bedke J, Zhang J, Maurer MA, Simsek B, Ejzykowicz F, Schwab GM, Apolo AB, Motzer RJ; CheckMate 9ER Investigators. Choueiri TK, et al. N Engl J Med. 2021 Mar 4;384(9):829-841. doi: 10.1056/NEJMoa2026982. N Engl J Med. 2021. PMID: 33657295 Free PMC article. Clinical Trial.
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J, Selle F, Sehouli J, Lorusso D, Guerra Alía EM, Reinthaller A, Nagao S, Lefeuvre-Plesse C, Canzler U, Scambia G, Lortholary A, Marmé F, Combe P, de Gregorio N, Rodrigues M, Buderath P, Dubot C, Burges A, You B, Pujade-Lauraine E, Harter P; PAOLA-1 Investigators. Ray-Coquard I, et al. N Engl J Med. 2019 Dec 19;381(25):2416-2428. doi: 10.1056/NEJMoa1911361. N Engl J Med. 2019. PMID: 31851799 Clinical Trial.
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Lorusso D, Mouret-Reynier MA, Harter P, Cropet C, Caballero C, Wolfrum-Ristau P, Satoh T, Vergote I, Parma G, Nøttrup TJ, Lebreton C, Fasching PA, Pisano C, Manso L, Bourgeois H, Runnebaum I, Zamagni C, Hardy-Bessard AC, Schnelzer A, Fabbro M, Schmalfeldt B, Berton D, Belau A, Lotz JP, Gropp-Meier M, Gladieff L, Lück HJ, Abadie-Lacourtoisie S, Pujade-Lauraine E, Ray-Coquard I. Lorusso D, et al. Among authors: caballero c. Int J Gynecol Cancer. 2024 Apr 1;34(4):550-558. doi: 10.1136/ijgc-2023-004995. Int J Gynecol Cancer. 2024. PMID: 38129136 Free PMC article. Clinical Trial.
Effect of a Lifestyle Intervention Program With Energy-Restricted Mediterranean Diet and Exercise on Weight Loss and Cardiovascular Risk Factors: One-Year Results of the PREDIMED-Plus Trial.
Salas-Salvadó J, Díaz-López A, Ruiz-Canela M, Basora J, Fitó M, Corella D, Serra-Majem L, Wärnberg J, Romaguera D, Estruch R, Vidal J, Martínez JA, Arós F, Vázquez C, Ros E, Vioque J, López-Miranda J, Bueno-Cavanillas A, Tur JA, Tinahones FJ, Martín V, Lapetra J, Pintó X, Daimiel L, Delgado-Rodríguez M, Matía P, Gómez-Gracia E, Díez-Espino J, Babio N, Castañer O, Sorlí JV, Fiol M, Zulet MÁ, Bulló M, Goday A, Martínez-González MÁ; PREDIMED-Plus investigators. Salas-Salvadó J, et al. Diabetes Care. 2019 May;42(5):777-788. doi: 10.2337/dc18-0836. Epub 2018 Nov 2. Diabetes Care. 2019. PMID: 30389673 Free article. Clinical Trial.
Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update.
Loibl S, Jassem J, Sonnenblick A, Parlier D, Winer E, Bergh J, Gelber RD, Restuccia E, Im YH, Huang CS, Dalenc F, Calvo I, Procter M, Caballero C, Clark E, Raimbault A, McConnell R, Monturus E, de Azambuja E, Gomez HL, Bliss J, Viale G, Bines J, Piccart M; APHINITY Steering Committee and Investigators. Loibl S, et al. Among authors: caballero c. J Clin Oncol. 2024 Nov;42(31):3643-3651. doi: 10.1200/JCO.23.02505. Epub 2024 Sep 11. J Clin Oncol. 2024. PMID: 39259927 Clinical Trial.
La priorización de la investigación es un ejercicio ético: lecciones del Foro Global de Bioética en la Investigación para la Región de las Américas.
Saenz C, Carracedo S, Caballero C, Hurtado C, Leite Ribeiro A, Luna F, Ortiz Z, Palmero A, Peralta G, Ponce Testino R, Reveiz L, Sisa I. Saenz C, et al. Among authors: caballero c. Rev Panam Salud Publica. 2024 Mar 8;48:e26. doi: 10.26633/RPSP.2024.26. eCollection 2024. Rev Panam Salud Publica. 2024. PMID: 38464874 Free PMC article. Spanish. No abstract available.
[Obstructive Sleep Apnea].
Roncero A, Castro S, Herrero J, Romero S, Caballero C, Rodriguez P. Roncero A, et al. Among authors: caballero c. Open Respir Arch. 2022 Jun 9;4(3):100185. doi: 10.1016/j.opresp.2022.100185. eCollection 2022 Jul-Sep. Open Respir Arch. 2022. PMID: 37496584 Free PMC article. Spanish.
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative.
Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Gal-Yam EN, Robson ME, Ndozeng J, Di Leo A, Ciruelos EM, de Azambuja E, Viale G, Scheepers ED, Curigliano G, Bliss JM, Reis-Filho JS, Colleoni M, Balic M, Cardoso F, Albanell J, Duhem C, Marreaud S, Romagnoli D, Rojas B, Gombos A, Wildiers H, Guerrero-Zotano A, Hall P, Bonetti A, Larsson KF, Degiorgis M, Khodaverdi S, Greil R, Sverrisdóttir Á, Paoli M, Seyll E, Loibl S, Linderholm B, Zoppoli G, Davidson NE, Johannsson OT, Bedard PL, Loi S, Knox S, Cameron DA, Harbeck N, Montoya ML, Brandão M, Vingiani A, Caballero C, Hilbers FS, Yates LR, Benelli M, Venet D, Piccart MJ. Aftimos P, et al. Among authors: caballero c. Cancer Discov. 2021 Nov;11(11):2796-2811. doi: 10.1158/2159-8290.CD-20-1647. Epub 2021 Jun 28. Cancer Discov. 2021. PMID: 34183353 Free PMC article.
Targeting aldolase A in hepatocellular carcinoma leads to imbalanced glycolysis and energy stress due to uncontrolled FBP accumulation.
Snaebjornsson MT, Poeller P, Komkova D, Röhrig F, Schlicker L, Winkelkotte AM, Chaves-Filho AB, Al-Shami KM, Caballero CD, Koltsaki I, Vogel FCE, Frias-Soler RC, Rudalska R, Schwarz JD, Wolf E, Dauch D, Steuer R, Schulze A. Snaebjornsson MT, et al. Among authors: caballero cd. Nat Metab. 2025 Feb;7(2):348-366. doi: 10.1038/s42255-024-01201-w. Epub 2025 Jan 20. Nat Metab. 2025. PMID: 39833612 Free PMC article.
p53 deficient breast cancer cells reprogram preadipocytes toward tumor-protective immunomodulatory cells.
Hassin O, Sernik M, Seligman A, Vogel FCE, Wellenstein MD, Smollich J, Halperin C, Pirona AC, Toledano LN, Caballero CD, Schlicker L, Salame TM, Sarusi Portuguez A, Aylon Y, Scherz-Shouval R, Geiger T, de Visser KE, Schulze A, Oren M. Hassin O, et al. Among authors: caballero cd. Proc Natl Acad Sci U S A. 2023 Dec 26;120(52):e2311460120. doi: 10.1073/pnas.2311460120. Epub 2023 Dec 21. Proc Natl Acad Sci U S A. 2023. PMID: 38127986 Free PMC article.
263 results